Developing new monoclonal antibodies for aggressive lymphoma: A challenging road in the rituximab era

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5297-5298

  Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD22 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPRATUZUMAB; IMMUNOMEDICS; MONOCLONAL ANTIBODY; NEW DRUG; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANTIGENICITY; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CROSS REACTION; CYTOTOXICITY; DISEASE COURSE; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FLUSHING; HUMAN; INFECTION; LYMPHOCYTOPENIA; LYMPHOMA; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIDE EFFECT; TOXICITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL; PREDNISONE; VINCRISTINE;

EID: 4143052495     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0922     Document Type: Editorial

References (13)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 1993;328:1002-6.
3. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503.
4. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32.
5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
6. Haberman TM, Weller EA, Morrison VA, et al. Phase III trial of rituximab-CHOP vs. CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B cell lymphoma. Blood 2003;102:6a.
7. Coleman M, Goldenberg DM, Siegel AB, et al. Epratuzumab: targeting B-cell malignancies through CD22. Clin Cancer Res 2003;9: 3991S-4S.
8. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab (Humanized anti-Cd22 antibody) in aggressive non-Hodgkin's lymphoma: phase 1/2 clinical trial results. Clin Cancer Res 2004;10:5327-34.
9. Leonard J, Coleman M, Matthews J, et al. High complete response rate following epratuzumab (anti-CD22) and rituximab (anti-CD20) combination antibody therapy in follicular non-Hodgkin's lymphoma. Ann Oncol 2002;13:38.
10. Emmanouilides C, Leonard JP, Schuster SJ, et al. Multi-center, Phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood 2003;102:69a.
11. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-84.
12. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
13. Cesano A, Gayko U, Brannan C, Kapushoc H, Fields SZ, Perkins SL. Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma: Implications for targeted immunotherapy. Blood 2002;100:350a.